GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » LT-Debt-to-Total-Asset

Ectin Research AB (XSAT:ECTIN B) LT-Debt-to-Total-Asset : 0.17 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ectin Research AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.17.

Ectin Research AB's long-term debt to total assets ratio increased from Mar. 2023 (0.03) to Mar. 2024 (0.17). It may suggest that Ectin Research AB is progressively becoming more dependent on debt to grow their business.


Ectin Research AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ectin Research AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB LT-Debt-to-Total-Asset Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
LT-Debt-to-Total-Asset
0.07 0.07 0.03 0.11

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.04 0.11 0.17

Ectin Research AB LT-Debt-to-Total-Asset Calculation

Ectin Research AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.73/6.428
=

Ectin Research AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=0.76/4.418
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ectin Research AB  (XSAT:ECTIN B) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Ectin Research AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines